FRANKLIN, Mass., Feb. 5 /CNW/ -- Echo Therapeutics, Inc. (OTC Bulletin
Board: ECTE), a specialty pharmaceuticals and diabetes management company,
announced today that Patrick T. Mooney, M.D, Chairman and Chief Executive
Officer, will present at the RedChip Small-Cap Investor Conference on February
7, 2008 at 3:50 pm Mountain Standard Time (5:50 pm Eastern Standard Time).
The conference will be held at the Four Seasons Resort in Scottsdale, Arizona.
A live video webcast of the presentation will be available on the RedChip
Small-Cap Investor Conference website,
http://www.visualwebcaster.com/RedChipfeb2008/. A replay of the webcast and
the corresponding presentation will be available on Echo Therapeutics' website
shortly following the live presentation.
About Echo Therapeutics
Echo Therapeutics is a platform-enabled, specialty pharmaceuticals and
diabetes management company leveraging its expertise in transdermal science to
develop and commercialize non-invasive specialty pharmaceutical products and
medical devices. Echo's Symphony(TM) CTGM System is a next generation needle-
free, wireless, continuous transdermal glucose monitoring (CTGM) system for
diabetes home use and emerging hospital critical care markets. Symphony is
designed to provide on-demand glucose data conveniently, continuously and
cost-effectively. Symphony incorporates Echo's patented feedback mechanism for
optimal skin permeation control and its continuous transdermal biosensor. With
Symphony, Echo is focused on changing the paradigm of invasive, episodic
glucose testing in diabetes home use and hospital critical care settings. Echo
is also marshalling the potential of its patented AzoneTS(TM) transdermal drug
delivery technology to build an extensive pipeline of advanced topical
reformulations of FDA-approved products in accordance with the FDA's Section
505(b)(2) guidelines. Echo has submitted a New Drug Application (NDA) to the
FDA for the approval of its lead AzoneTS-based product candidate,
Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.
This press release contains forward-looking information that involves
risks and uncertainties, including statements regarding Echo's development
plans, objectives, expectations and intentions, including, without limitation,
statements regarding the Company's Symphony and AzoneTS product candidates.
Factors that could adversely affect Echo's business and prospects are
described in the Company's filings with the Securities and Exchange
Commission. Echo expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect any change
in the Company's expectations or any change in events, conditions or
circumstances on which any such statement is based.
Investor Relations Contacts:
Patrick T. Mooney, M.D.
Chairman & CEO
Stern Investor Relations
For further information:
For further information: Patrick T. Mooney, M.D., Chairman & CEO of Echo
Therapeutics, +1-508-530-0329; or Lilian Stern of Stern Investor Relations,
+1-212-362-1200, for Echo Therapeutics Web Site: